SYDNEY, July 20, 2026, 10:14 AEST
- Telix ended Friday at A$14.91, marking an 8.36% decline across five sessions. The S&P/ASX 200 fell 0.11%.
- Enrollment in Japan Phase 3 has included 105 patients. Conditional approval continues to be evaluated.
- Telix’s revenue outlook for 2026 includes only approved markets, excluding Japan from the forecast.
Telix Pharmaceuticals Ltd (ASX:TLX; NASDAQ:TLX) opened Monday trading at A$14.91, its last available price. Shares dropped 4.48% on Friday. Australia’s cash market was active, though Google Finance continued to display Friday’s data.
Guidance is the main benchmark for valuation. Telix projects 2026 revenue between US$950 million and US$970 million, reflecting approved products and markets. In Japan, Illuccix is still under investigation.
Japan thus remains a possible area of upside not included in guidance. The enrollment milestone was given minimal immediate value in Friday’s trading.
Telix enrolled 105 participants at 11 sites in Japan. The study evaluates the sensitivity of PSMA-PET against CT and bone scans for detecting recurrence after surgery.
The information will back a Japanese new drug application. A request for conditional approval is still being evaluated by the PMDA. Telix did not specify when a decision is expected.
In March, the PMDA stated that no PSMA-PET drug was authorised in Japan for initial staging or identification of recurrent disease. Japan expects 99,900 new prostate cancer cases in 2025, but just a portion would be eligible for Telix’s intended indication.
The contrast is clear:
| Measure | Telix | Reference | Gap or ratio |
|---|---|---|---|
| Friday return | -4.48% | ASX 200: -0.50%, at 8,796.70 | -3.98 percentage points |
| Five-session return | -8.36% | ASX 200: -0.11% | -8.25 percentage points |
| Friday volume | 2.13 million | Four-day average prior: 1.05 million | 2.03 times |
| Price target | RBC: A$18 | Average for 14 analysts: A$23.35 | 20.7% and 56.6% above close |
Telix underperformed the index by 8.25 percentage points over five sessions. Trading volume on Friday reached 2.03 times the average of the previous four sessions. Broad market softness did not fully account for the movement.
On Friday, RBC Capital Markets downgraded Telix from Outperform to Sector Perform. The firm maintained its price target at A$18, representing a 20.7% premium to the previous close.
According to MarketScreener’s consensus of 14 analysts, the average target is A$23.35, with the lowest at A$18. Every target in the range is higher than the current market price.
David N. Cade, group chief medical officer at Telix, described enrollment as “a significant step towards the registration of Illuccix in Japan.” He noted that recruitment had proceeded quickly at 11 sites. Telix Pharmaceuticals
Novartis AG NYSE:NVS secured Japanese approval for Locametz in September 2025. The label authorizes use in selecting patients for PSMA-targeted therapy, not for identifying recurrent disease.
Telix projects 2026 research and development expenditure to range between US$200 million and US$240 million. Rapid regulatory progress would support the rationale for this level of investment, positioning approval as the key hurdle.
Risks are evident: conditional approval could face postponement or rejection. The trial might not reach endpoints, and uncertainty persists regarding reimbursement and the level of eligible demand.
The upcoming reassessment will be by regulators. Japan does not enter the disclosed revenue bracket until the PMDA makes its decision.
